Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Severe-Bleeding Workshop Addresses Need For Effective Local Agents

This article was originally published in The Gray Sheet

Executive Summary

Panelists at a recent FDA workshop on severe bleeding said there is a need for effective local agents to treat severe bleeding in trauma and surgical cases, and explored a set of primary clinical endpoints for studying the products in rigorous trials.

You may also be interested in...

New Products In Brief

Recent debuts and approvals include Covidien’s AS Meniscal repair device, Medtronic’s Sentrino continuous glucose management system and Blue Belt’s NavioPFS system for partial knee replacement.

News In Brief

Genzyme unloads Dx unit

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts